Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01134

Contribution of Different PET Tracers in Glioma Management: Focus on Glioblastoma

 Aurélie Moreau1, 2*, Olivia Febvey1,  Thomas Mognetti1, Didier Frappaz1 and David Kryza2, 3
  • 1Centre Léon Bérard, France
  • 2UMR5007 Laboratoire d'Automatique et de Genie Des Procedes (LAGEP), France
  • 3Hospices Civils de Lyon, France

Although rare, glioblastomas account for the majority of primary brain lesions, with a dreadful prognosis.
Magnetic Resonance Imaging (MRI) is currently the imaging method providing the higher resolution. However, it does not always succeed in distinguishing recurrences from nonspecific post-therapeutic-related changes caused by the combination of radiotherapy, chemotherapy and targeted therapy, also called pseudoprogression. Strenuous attempts to overcome this issue is highly required for these patients with a short life expectancy, for both ethical and economic reasons. Additional reliable information may be obtained from positron emission tomography (PET) imaging. The development of this technique along with the emerging of new classes of tracers can help in diagnosis, prognosis and assessment of therapies. We reviewed the current data about the commonly used tracers such as 18F-Fluorodeoxyglucose (18F-FDG) and radiolabeled amino-acids, as well as different PET tracers recently investigated to report their strengths, limitations and their relevance in glioblastoma management.

Keywords: Gliobalstoma, PET - Positron Emission Tomography, FDG (2-[ 18F]-fluoro-2-deoxy-D-glucose), Fluorodopa (18F), Radiolabeled amino acids, PSMA

Received: 30 Apr 2019; Accepted: 10 Oct 2019.

Copyright: © 2019 Moreau, Febvey, Mognetti, Frappaz and Kryza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Aurélie Moreau, Centre Léon Bérard, Lyon, France, aurelie.moreau@lyon.unicancer.fr